Aeglea’s Rare Disease Asset Succeeds At Phase III, In Line To Become First Product
BLA Filing Expected Next Year
The firm’s lead candidate has shown promise in a pivotal rare disease study, setting it on track for an upcoming BLA catalyst which could lead to Aeglea’s first approved product.
You may also be interested in...
Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.